Adverum Historical Financial Ratios
ADVM Stock | USD 10.43 0.43 4.30% |
Adverum Biotechnologies is presently reporting on over 109 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.96 or Days Sales Outstanding of 263 will help investors to properly organize and evaluate Adverum Biotechnologies financial condition quickly.
Adverum |
About Adverum Financial Ratios Analysis
Adverum BiotechnologiesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Adverum Biotechnologies investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Adverum financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Adverum Biotechnologies history.
Adverum Biotechnologies Financial Ratios Chart
Adverum Biotechnologies financial ratios usually calculated using numerical values taken directly from Adverum Biotechnologies financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about Adverum Biotechnologies. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At this time, Adverum Biotechnologies' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 4th of May 2024, Research And Ddevelopement To Revenue is likely to grow to 28.66, though Free Cash Flow Yield is likely to grow to (1.15). Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Adverum Biotechnologies stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Adverum Biotechnologies sales, a figure that is much harder to manipulate than other Adverum Biotechnologies multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Adverum Biotechnologies' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Adverum Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.At this time, Adverum Biotechnologies' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 4th of May 2024, Research And Ddevelopement To Revenue is likely to grow to 28.66, though Free Cash Flow Yield is likely to grow to (1.15).
2023 | 2024 (projected) | Graham Number | 46.53 | 33.97 | Receivables Turnover | 1.51 | 2.98 |
Adverum Biotechnologies fundamentals Correlations
Click cells to compare fundamentals
Adverum Biotechnologies Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adverum Biotechnologies fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 1.2K | 3.0K | 23.01 | 21.09 | 24.25 | 23.04 | |
Ptb Ratio | 4.22 | 2.12 | 0.55 | 0.32 | 0.91 | 0.96 | |
Book Value Per Share | 27.29 | 51.01 | 32.25 | 18.29 | 8.28 | 11.14 | |
Free Cash Flow Yield | (0.0926) | (0.0987) | (0.71) | (2.08) | (1.21) | (1.15) | |
Operating Cash Flow Per Share | (7.67) | (9.31) | (11.0) | (10.89) | (9.06) | (9.51) | |
Capex To Depreciation | (12.24) | (2.85) | (3.26) | (1.81) | (0.14) | (0.15) | |
Pb Ratio | 4.22 | 2.12 | 0.55 | 0.32 | 0.91 | 0.96 | |
Ev To Sales | 1.1K | 2.8K | 32.18 | 21.1 | 24.26 | 23.05 | |
Free Cash Flow Per Share | (10.67) | (10.7) | (12.54) | (12.08) | (9.14) | (9.59) | |
Roic | (0.33) | (0.26) | (0.35) | (0.55) | (0.77) | (0.74) | |
Net Income Per Share | (10.06) | (13.8) | (14.85) | (15.57) | (11.62) | (12.2) | |
Sales General And Administrative To Revenue | 15.24 | 113.5 | 8.59 | 13.87 | 12.48 | 17.94 | |
Research And Ddevelopement To Revenue | 31.1 | 161.68 | 11.89 | 21.52 | 19.37 | 28.66 | |
Capex To Revenue | (0.5) | (76.99) | (2.02) | (0.22) | (0.26) | (0.27) | |
Cash Per Share | 25.9 | 50.47 | 31.13 | 18.7 | 9.57 | 11.22 | |
Pocfratio | (15.02) | (11.64) | (1.6) | (0.53) | (0.83) | (0.87) | |
Capex To Operating Cash Flow | 0.39 | 0.15 | 0.14 | 0.11 | 0.008848 | 0.008405 | |
Pfcf Ratio | (10.79) | (10.13) | (1.4) | (0.48) | (0.82) | (0.87) | |
Roe | (0.37) | (0.27) | (0.46) | (0.85) | (1.4) | (1.33) | |
Ev To Operating Cash Flow | (14.33) | (11.24) | (2.24) | (0.89) | (0.83) | (0.87) | |
Pe Ratio | (11.45) | (7.85) | (1.19) | (0.37) | (0.65) | (0.68) | |
Ev To Free Cash Flow | (10.3) | (9.78) | (1.96) | (0.8) | (0.82) | (0.87) | |
Earnings Yield | (0.0873) | (0.13) | (0.84) | (2.68) | (1.54) | (1.47) | |
Net Debt To E B I T D A | 0.5 | 0.28 | (0.49) | (0.25) | (3.05E-4) | (3.2E-4) | |
Current Ratio | 9.06 | 20.82 | 14.88 | 5.91 | 4.13 | 3.92 | |
Tangible Book Value Per Share | 27.29 | 51.01 | 32.25 | 18.29 | 8.28 | 11.11 | |
Graham Number | 78.6 | 125.86 | 103.79 | 80.04 | 46.53 | 33.97 | |
Shareholders Equity Per Share | 27.29 | 51.01 | 32.25 | 18.29 | 8.28 | 11.14 | |
Capex Per Share | (3.0) | (1.39) | (1.54) | (1.19) | (0.0801) | (0.0841) | |
Graham Net Net | 18.45 | 44.81 | 18.96 | 5.92 | 0.69 | 0.66 |
Pair Trading with Adverum Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adverum Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adverum Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Adverum Stock
0.72 | VRAX | Virax Biolabs Group Fiscal Year End 12th of June 2024 | PairCorr |
Moving against Adverum Stock
0.6 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
0.58 | LIXT | Lixte Biotechnology Earnings Call This Week | PairCorr |
0.5 | GBIO | Generation BioCo Financial Report 8th of May 2024 | PairCorr |
0.49 | ELVN | Enliven Therapeutics Trending | PairCorr |
The ability to find closely correlated positions to Adverum Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adverum Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adverum Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adverum Biotechnologies to buy it.
The correlation of Adverum Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adverum Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adverum Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adverum Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Adverum Stock analysis
When running Adverum Biotechnologies' price analysis, check to measure Adverum Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adverum Biotechnologies is operating at the current time. Most of Adverum Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adverum Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adverum Biotechnologies' price. Additionally, you may evaluate how the addition of Adverum Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Adverum Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.60) | Revenue Per Share 0.357 | Quarterly Revenue Growth (0.70) | Return On Assets (0.32) | Return On Equity (0.88) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.